You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 13, 2024

TRIESENCE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Triesence patents expire, and when can generic versions of Triesence launch?

Triesence is a drug marketed by Harrow Eye and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-five patent family members in twenty-one countries.

The generic ingredient in TRIESENCE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-one suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Triesence

A generic version of TRIESENCE was approved as triamcinolone acetonide by TARO on October 1st, 1986.

  Sign Up

Summary for TRIESENCE
Drug patent expirations by year for TRIESENCE
Drug Prices for TRIESENCE

See drug prices for TRIESENCE

Recent Clinical Trials for TRIESENCE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Oxular LimitedPhase 2
Wake Forest University Health SciencesPhase 4
Duke UniversityN/A

See all TRIESENCE clinical trials

Pharmacology for TRIESENCE

US Patents and Regulatory Information for TRIESENCE

TRIESENCE is protected by three US patents.

Patents protecting TRIESENCE

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: VISUALIZATION DURING VITRECTOMY PROCEDURES

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF OPHTHALMIC DISORDERS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Harrow Eye TRIESENCE triamcinolone acetonide INJECTABLE;INTRAVITREAL 022048-001 Nov 29, 2007 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Harrow Eye TRIESENCE triamcinolone acetonide INJECTABLE;INTRAVITREAL 022048-001 Nov 29, 2007 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TRIESENCE

See the table below for patents covering TRIESENCE around the world.

Country Patent Number Title Estimated Expiration
Taiwan I468165 ⤷  Sign Up
Taiwan 200940071 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection ⤷  Sign Up
Slovenia 2262506 ⤷  Sign Up
Russian Federation 2481842 НИЗКОВЯЗКИЕ ВЫСОКОФЛОКУЛИРОВАННЫЕ СУСПЕНЗИИ ТРИАМЦИНОЛОНА АЦЕТОНИДА ДЛЯ ИНТРАВИТРЕАЛЬНЫХ ИНЪЕКЦИЙ (LOW-VISCOUS HIGHLY FLOCCULATED TRIAMCINOLONE ACETONIDE SUSPENSIONS FOR INTRAVITREAL INJECTIONS) ⤷  Sign Up
Argentina 070824 SUSPENSIONES PARA INYECCION INTRAVITREA DE TRIAMCINOLONA ACETONIDO DE BAJA VISCOSIDAD, ALTAMENTE FLOCULADAS ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.